Garivulimab (BGB-A333) 是一种人源化 IgG1 变体单克隆抗体，可特异性靶向并结合
PD-L1。Garivulimab 选择性地阻断 PD-L1 和 PD-1 的相互作用，具有抗肿瘤活性。
| 生物活性 |
Garivulimab (BGB-A333) is a humanized IgG1-variant monoclonal antibody that specifically targets and binds toPD-L1. Garivulimab selectively blocks the interaction ofPD-L1andPD-1. Garivulimab has antitumor activity[1].
|
体外研究
(In Vitro) |
Garivulimab (BGB-A333) specifically targets and binds to PD-L1, blocking interaction to its receptor, PD-1 on T cell, reversing T cell inactivation, and increases T cell expansion resulting in cytotoxic T cell-mediated antitumor immune response against PD-L1-expressing tumor cells. Garivulimab also inhibits PD-L1-induced apoptosis of activated CD8+ T cells and increases T cell proliferation[1].
|
| CAS 号 |
|
| 储存方式 |
Please store the product under the recommended conditions in the Certificate of Analysis.
|
m.cnreagent.com
